ABSTRACT
SUMMARY OBJECTIVE: The aim of this study was to investigate the efficacy of platelet-rich plasma injection on the olfactory cleft of patients with post-COVID olfactory dysfunction lasting over 1 year, who were unresponsive to common treatments. METHODS: Patients over 18 years of age with post-COVID olfactory dysfunction over 1 year whose complaints did not improve with intranasal steroids and D-panthenol/vitamin A combination nasal sprays with olfactory rehabilitation training for 1 month were prospectively collected and randomized into two groups: intranasal platelet-rich plasma group and control group. At the end of 1 month, Connecticut Chemosensory Clinical Research Center olfaction test scores of smell detection threshold and smell identification test were compared accordingly. RESULTS: A total of 25 patients were randomized into platelet-rich plasma (n=12) and control (n=13) groups. In the platelet-rich plasma group, the mean smell detection threshold score increased from 5.63 (SD 0.68) to 6.46 (SD 0.45), and the mean smell identification test score increased from 11.42 (SD 1.17) to 15.17 (SD 0.39). In the control group, the mean smell detection threshold score changed from 5.69 (SD 0.66) to 5.77 (SD 0.70), and the mean smell identification test score changed from 11.20 (SD 1.12) to 11.85 (SD 1.57). Post-hoc analysis revealed that similar mean smell detection threshold (mean difference 0.07; p=0.994) and smell identification test (mean difference −0.50; p=0.703) scores were transformed into a significant difference between groups (smell detection threshold mean difference 0.69; p=0.037; smell identification test mean difference 3.32; p<0.001). CONCLUSION: At the end of the first month, there was a significant improvement in olfactory threshold values in the platelet-rich plasma group compared to the control group. No side effect or adverse event related to platelet-rich plasma injection was observed.
ABSTRACT
Se estima que entre el 0,8 y 1,42% de la población general presenta algún grado de disfunción olfativa. En estudios epidemiológicos de población general han demostrado que esto aumenta con la edad, llegando a afectar al 29% de las personas entre 70 y 79 años. Las causas más comunes del déficit de olfacción en el adulto mayor son trauma de cráneo, inflamación del tracto respiratorio alto de etiología tanto infecciosa como alérgica y las enfermedades degenerativas del sistema nervioso central como la enfermedad de Alzheimer y de Parkinson. El 60 al 90% de los pacientes con Enfermedad de Párkinson tiene déficit olfativo, siendo uno de los síntomas más frecuentes de la enfermedad. Se presenta en forma precoz y bilateral, el déficit en general no es a todos los olores, permaneciendo la habilidad de reconocer algunos. En esta revisión, se caracteriza la forma de presentación de este trastorno y su impacto como un marcador biológico en la enfermedad de Parkinson...
Between 0,8 to 1,42% of the population presents some grade of smell dysfunction. Several epidemiological studies have demonstrated that this increases with the age, affecting to 29% of subjects between 70 and 79 years. The more common causes of this dysfunction are skull trauma, inflammation of upper respiratory tract of infectious or allergic etiologies and the degenerative diseases of the central nervous system, mainly Alzheimer and Parkinson disease. Between 60 to 90% of the patients with Parkinson Disease have smell deficit, being one of the more common symptoms in this disease. Usually this smell dysfunction is presented bilaterally and it appears early in the course of the disease. In this review is characterized the clinical presentation of this dysfunction and its impact as a biological marker in the PD...